📣 VC round data is live. Check it out!

Asterasys Valuation Multiples

Discover revenue and EBITDA valuation multiples for Asterasys and similar public comparables like Medinice, Ilex Medical, RxSight, Lucid Diagnostics and more.

Asterasys Overview

About Asterasys

Asterasys Co Ltd is a professional healthcare and biomedical corporation based in Korea. It is engaged in the Manufacture of electro-diagnostic and electro-therapeutic apparatuses featuring body composition analyzers such as the InBalance series and HIFU systems such as the Liftera series, it provides total solutions with healthcare, skincare, and IoT-oriented services that can connect with its product portfolio.


Founded

2015

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $30M
EBITDA: $10M

EV

$190M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Asterasys Financials

Asterasys reported last 12-month revenue of $30M and EBITDA of $10M.

In the same LTM period, Asterasys generated $24M in gross profit, $10M in EBITDA, and $8M in net income.

Revenue (LTM)


Asterasys P&L

In the most recent fiscal year, Asterasys reported revenue of $25M and EBITDA of $8M.

Asterasys is profitable as of last fiscal year, with gross margin of 78%, EBITDA margin of 33%, and net margin of 24%.

See analyst estimates for Asterasys
LTMLast FY202320242025202620272028
Revenue$30M$25M$12M$19M$25M
Gross Profit$24M$20M$9M$14M$20M
Gross Margin79%78%74%72%79%
EBITDA$10M$8M$2M$6M$8M
EBITDA Margin35%33%17%29%33%
EBIT Margin31%28%9%23%27%
Net Profit$8M$6M$577K$4M$6M
Net Margin26%24%5%19%24%

Financial data powered by Morningstar, Inc.

Asterasys Stock Performance

Asterasys has current market cap of $202M, and enterprise value of $190M.

Market Cap Evolution


Asterasys' stock price is $5.37.

Asterasys share price decreased by 5.5% in the last 30 days, and by 35.0% in the last year.

Asterasys has an EPS (earnings per share) of $0.16.

See more trading valuation data for Asterasys
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$190M$202M-2.0%-5.5%-27.5%-35.0%$0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Asterasys Valuation Multiples

Asterasys trades at 6.3x EV/Revenue multiple, and 18.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Asterasys

EV / Revenue (LTM)


Asterasys Financial Valuation Multiples

As of June 3, 2026, Asterasys has market cap of $202M and EV of $190M.

Asterasys has a P/E ratio of 25.6x.

LTMLast FY202320242025202620272028
EV/Revenue6.3x7.5x16.4x10.0x7.6x
EV/EBITDA18.2x22.7x96.6x34.1x22.7x
EV/EBIT20.3x27.3x184.8x43.1x27.7x
EV/Gross Profit8.0x9.6x22.2x13.8x9.6x
P/E25.6x33.1xn/m56.9x33.1x
EV/FCF32.9x82.4xn/m91.9x82.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Asterasys Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Asterasys Margins & Growth Rates

Asterasys grew revenue by 44% and EBITDA by 61% in the last fiscal year.

In the most recent fiscal year, Asterasys reported gross margin of 78%, EBITDA margin of 33%, and net margin of 24%.

See estimated margins and future growth rates for Asterasys

Asterasys Margins

Last FY202420252026202720282029
Gross Margin78%72%79%78%
EBITDA Margin33%29%33%37%
EBIT Margin28%23%27%35%
Net Margin24%19%24%29%
FCF Margin9%11%9%33%

Asterasys Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth44%65%32%45%
Gross Profit Growth44%61%44%44%
EBITDA Growth61%183%50%61%
EBIT Growth81%329%56%84%
Net Profit Growth75%514%72%75%
FCF Growth415%(2800%)11%415%

Data powered by FactSet, Inc. and Morningstar, Inc.

Asterasys Operational KPIs

Asterasys' Rule of 40 is 82% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Asterasys' Rule of X is 150% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Asterasys
LTMLast FY202320242025202620272028
Rule of 4075%82%---
Bessemer Rule of X134%150%---
S&M Expenses to Revenue-27%27%24%27%
G&A Expenses to Revenue-1%2%1%1%
R&D Expenses to Revenue-9%15%9%9%
Opex to Revenue-51%65%49%52%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Asterasys Competitors

Asterasys competitors include Medinice, Ilex Medical, RxSight, Lucid Diagnostics, TriSalus Life Sciences, Sanara MedTech, Anika Therapeutics, Pro-Dex, Huons Co and Utah Medical.

Most Asterasys public comparables operate across IoT, Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medinice--(111.9x)-
Ilex Medical0.4x-3.3x-
RxSight(0.0x)(0.0x)0.1x0.0x
Lucid Diagnostics44.1x35.6x(3.7x)(4.0x)
TriSalus Life Sciences4.0x3.7x(11.1x)(12.2x)
Sanara MedTech2.2x2.1x13.6x13.7x
Anika Therapeutics1.6x1.5x33.0x24.0x
Pro-Dex3.3x2.9x15.7x-

This data is available for Pro users. Sign up to see all Asterasys competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Asterasys

When was Asterasys founded?Asterasys was founded in 2015.
Where is Asterasys headquartered?Asterasys is headquartered in South Korea.
Is Asterasys publicly listed?Yes, Asterasys is a public company listed on Korea Exchange.
What is the stock symbol of Asterasys?Asterasys trades under 450950 ticker.
When did Asterasys go public?Asterasys went public in 2025.
Who are competitors of Asterasys?Asterasys main competitors include Medinice, Ilex Medical, RxSight, Lucid Diagnostics, TriSalus Life Sciences, Sanara MedTech, Anika Therapeutics, Pro-Dex, Huons Co, Utah Medical.
What is the current market cap of Asterasys?Asterasys' current market cap is $202M.
What is the current revenue of Asterasys?Asterasys' last 12 months revenue is $30M.
What is the current revenue growth of Asterasys?Asterasys revenue growth (NTM/LTM) is 40%.
What is the current EV/Revenue multiple of Asterasys?Current revenue multiple of Asterasys is 6.3x.
What is the current EBITDA of Asterasys?Asterasys' last 12 months EBITDA is $10M.
What is Asterasys' EBITDA margin?Asterasys' last 12 months EBITDA margin is 35%.
What is the current EV/EBITDA multiple of Asterasys?Current EBITDA multiple of Asterasys is 18.2x.
What is the current FCF of Asterasys?Asterasys' last 12 months FCF is $6M.
What is Asterasys' FCF margin?Asterasys' last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Asterasys?Current FCF multiple of Asterasys is 32.9x.
How many companies Asterasys has acquired to date?Asterasys hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Asterasys has invested to date?Asterasys hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Asterasys

Lists including Asterasys

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial